Search Result

Results for "

APD

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (3) Adrenergic Receptor (2) Apoptosis (2) Autophagy (5) Bacterial (4) Cannabinoid Receptor (1) Cytochrome P450 (1) Endogenous Metabolite (1) GPR119 (2) Histamine Receptor (1) HMG-CoA Reductase (HMGCR) (5) Isotope-Labeled Compounds (3) LPL Receptor (2) LXR (1) Monoamine Transporter (1) Potassium Channel (14) Prostaglandin Receptor (1) Sodium Channel (3)
By Research Areas:	Cancer (6) Cardiovascular Disease (16) Endocrinology (3) Inflammation/Immunology (2) Metabolic Disease (7) Neurological Disease (6)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-125772

Acetyl podocarpic acid anhydride Acetylpodocarpic dimer; APD	LXR	Cardiovascular Disease
Acetyl podocarpic acid anhydride is a potent, semisynthetic liver X receptor(LXR) agonist derived from extracts of the mayapple. Acetyl podocarpic acid anhydride has the potential to be useful for the prevention and research of atherosclerosis, especially in the context of low HDL levels .

HY-15565

APD668 2 Publications Verification	GPR119 Cytochrome P450 Potassium Channel	Metabolic Disease
APD668 is a potent, selective and orally active agonist of G-protein coupled receptor GPR119, with EC₅₀s of 2.7 nM and 33 nM for hGPR119 and rGPR119, respectively. APD668 shows no significant inhibition of any of the five major CYP isoforms with the exception of CYP2C9 (K_i=0.1 μM). APD668 can be used for the research of steatohepatitis and diabetes .

HY-111110

Olorinab APD 371	Cannabinoid Receptor	Neurological Disease
Olorinab (APD 371) is a highly potent, selective and fully efficacious cannabinoid receptor type 2 (CB₂) agonist, with an EC₅₀ of 6.2 nM for hCB₂.

HY-15566

APD597 1 Publications Verification JNJ-38431055	GPR119	Metabolic Disease
APD597 is a GPR119 agonist intended for the treatment of type 2 diabetes, with EC50 of 46 nM for hGPR119.

HY-12789

Etrasimod 1 Publications Verification APD334	LPL Receptor	Inflammation/Immunology
Etrasimod (APD334) is a potent, selective and orally available antagonist of the sphingosine-1-phosphate-1 (S1P₁) receptor with an IC₅₀ value of 1.88 nM in CHO cells.

HY-10559

Nelotanserin 2 Publications Verification APD125	5-HT Receptor	Neurological Disease Cancer
Nelotanserin is a potent 5-HT_2A inverse agonist, a moderately potent 5-HT_2C partial inverse agonist and a weak 5-HT_2B inverse agonist, with IC₅₀s of 1.7, 79, 791 nM in IP accumulation assays, respectively.

HY-10560

Temanogrel APD791	5-HT Receptor	Neurological Disease
Temanogrel is a highly selective 5-HT_2A receptor antagonist with a K_i of 4.9 nM.

HY-16751

Ralinepag APD811	Prostaglandin Receptor	Cardiovascular Disease Endocrinology
Ralinepag is a potent, orally bioavailable and non-prostanoid prostacyclin (IP) receptor agonist, with EC₅₀s of 8.5 nM, 530 nM and 850 nM for human and rat IP receptor and human DP1 receptor, respectively.

HY-148804

Vemtoberant APD418	Adrenergic Receptor	Endocrinology
Vemtoberant is an β₃ Adrenergic Receptor antagonist. Vemtoberant can be used for research of β₃ adrenergic receptor-mediated disorder, such as, heart failure .

HY-19899

APD-916	Histamine Receptor	Neurological Disease
APD-916 is an H3 receptor antagonist. APD-916 shows good pharmacokinetic properties, and oral administration of APD-916 has been shown to enhance wakefulness in various animal models .

HY-148804A

Vemtoberant mesylate APD418 mesylate	Adrenergic Receptor	Endocrinology
Vemtoberant mesylate is an β₃ Adrenergic Receptor antagonist. Vemtoberant mesylate can be used for research of β₃ adrenergic receptor-mediated disorder, such as, heart failure .

HY-10560A

Temanogrel hydrochloride APD791 hydrochloride	5-HT Receptor	Neurological Disease
Temanogrel hydrochloride is a highly selective 5-HT_2A receptor antagonist with a K_i of 4.9 nM.

HY-135432

Etrasimod arginine APD334 arginine	LPL Receptor	Inflammation/Immunology
Etrasimod arginine is an orally available S1P receptor modulator that is a potent full agonist of the S1P1 receptor and has partial agonist activity at S1P4. Etrasimod arginine reduces inflammation in a CD4 ⁺CD45RB ^high T cell-transferred mouse colitis model .

HY-N0747

Oxypeucedanin	Potassium Channel Apoptosis	Cardiovascular Disease Cancer
Oxypeucedanin is a furocoumarin derivative isolated from Angelica dahurica. Oxypeucedanin is a selective open-channel blocker, inhibits the hKv1.5 current with an IC₅₀ value of 76 nM. Oxypeucedanin prolongs cardiac action potential duration (APD), is a potential antiarrhythmic agent for atrial fibrillation . Oxypeucedanin induces cell apoptosis through inhibition of cancer cell migration .

HY-N0747R

Oxypeucedanin (Standard)	Potassium Channel Apoptosis	Cardiovascular Disease Cancer
Oxypeucedanin (Standard) is the analytical standard of Oxypeucedanin. This product is intended for research and analytical applications. Oxypeucedanin is a furocoumarin derivative isolated from Angelica dahurica. Oxypeucedanin is a selective open-channel blocker, inhibits the hKv1.5 current with an IC₅₀ value of 76 nM.?Oxypeucedanin prolongs cardiac action potential duration (APD), is a potential antiarrhythmic agent for atrial fibrillation . Oxypeucedanin induces cell?apoptosis through inhibition of cancer cell migration .

HY-17504AS

Rosuvastatin-d3 ZD 4522 d₃	Isotope-Labeled Compounds HMG-CoA Reductase (HMGCR) Autophagy Potassium Channel	Cardiovascular Disease Metabolic Disease
Rosuvastatin-d₃ is a deuterium labeled Rosuvastatin. Rosuvastatin (ZD 4522) is a competitive HMG-CoA reductase inhibitor with an IC50 of 11 nM[1]. Rosuvastatin potently blocks human ether-a-go-go related gene (hERG) current with an IC50 of 195 nM, delayed cardiac repolarization, and thereby prolonged action potential durations (APDs) and corrected QT interval (QTc) intervals[2].

HY-W008628S

Bisphenol AP-d5	Isotope-Labeled Compounds	Others
Bisphenol AP-d₅ is the deuterium labeled Bisphenol AP[1].

HY-17504A

Rosuvastatin ZD 4522	HMG-CoA Reductase (HMGCR) Autophagy Potassium Channel Bacterial	Cardiovascular Disease Metabolic Disease Cancer
Rosuvastatin (ZD 4522) is a competitive HMG-CoA reductase inhibitor with an IC₅₀ of 11 nM. Rosuvastatin potently blocks hERG current with an IC₅₀ of 195 nM, delayed cardiac repolarization, and thereby prolonged action potential durations (APDs) and corrected QT interval (QTc) intervals. Rosuvastatin reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .

HY-W010950A

Flecainide hydrochloride 1 Publications Verification	Potassium Channel Sodium Channel	Cardiovascular Disease
Flecainide hydrochloride is a potent and orally active antiarrhythmic agent. Flecainide hydrochloride blocks the cardiac fast inward Na ⁺ current (INa) and the rapid component of the delayed rectifier K ⁺ current. Flecainide hydrochloride prolongs the action potential duration (APD) in ventricular and atrial muscle fibres. Flecainide hydrochloride has the potential for the research of fetal tachycardias .

HY-W010950

Flecainide 1 Publications Verification	Potassium Channel Sodium Channel	Cardiovascular Disease
Flecainide is a potent and orally active antiarrhythmic agent. Flecainide blocks the cardiac fast inward Na ⁺ current (INa) and the rapid component of the delayed rectifier K ⁺ current. Flecainide prolongs the action potential duration (APD) in ventricular and atrial muscle fibres. Flecainide has the potential for the research of fetal tachycardias .

HY-14924

Inakalant	Potassium Channel	Cardiovascular Disease
Inakalant is an atrial specific potassium channel blocker with antiarrhythmic activity. Inakalant works by selectively blocking potassium channels in heart cells, thereby prolongs the action potential duration (APD) of cardiomyocytes and increases the effective refractory period of the atria and ventricles, which helps to terminate and prevent the occurrence of arrhythmias such as atrial fibrillation (AF). Inakalant can be used in the study of arrhythmia and cardiac electrophysiology .

HY-W010950R

Flecainide (Standard)	Potassium Channel Sodium Channel	Cardiovascular Disease
Flecainide (Standard) is the analytical standard of Flecainide. This product is intended for research and analytical applications. Flecainide is a potent and orally active antiarrhythmic agent. Flecainide blocks the cardiac fast inward Na ⁺ current (INa) and the rapid component of the delayed rectifier K ⁺ current. Flecainide prolongs the action potential duration (APD) in ventricular and atrial muscle fibres. Flecainide has the potential for the research of fetal tachycardias .

HY-118148

UK-66914	Potassium Channel	Cardiovascular Disease
UK-66914, is a class III antiarrhythmic agent that specifically acts on the delayed rectifier potassium current (I_K). UK-66914 is designed to prolong action potential duration (APD) and increase cardiac refractory period, thereby potentially terminating the reentry mechanism in arrhythmias without affecting the serious side effects of antiarrhythmic drugs associated with other ion channels such as Na+ and Ca2+ currents .

HY-107036

BMS-394136	Potassium Channel	Cardiovascular Disease
BMS-394136 (compound 1) is a potent inhibitor of Kv 1.5, with an IC₅₀ of 0.05 μM. BMS-394136 is a selective IKur inhibitor. BMS-394136 dose-dependently prolongs atrial effective refractory period (AERP) and action potential duration (APD) without effecting ventricular effective refractory period (VERP). BMS-394136 can be used for acute atrial ischemia research .

HY-118317

Zacopride	Endogenous Metabolite	Cardiovascular Disease
Zacopride is a selective agonist with the activity of enhancing the inward rectifier potassium current (IK1) in rabbit hearts. Zacopride also exhibits significant antiarrhythmic effects, inhibiting ventricular arrhythmias by increasing IK1 without affecting atrial arrhythmias. Zacopride can hyperpolarize the resting membrane potential and shorten the action potential duration (APD) in a concentration-dependent manner. Zacopride significantly reduced the incidence of compound-induced early afterdepolarizations (EADs) at 1 μmol/L .

HY-15793

NBI-98782 1 Publications Verification (+)-DTBZ; (+)-α-Dihydrotetrabenazine; (+)-α-DHTBZ	Monoamine Transporter	Neurological Disease
NBI-98782 is a high affinity and selectivity vesicular monoamine transporter 2 (VMAT2) inhibitor with a K_i of 3 nM. NBI-98782 has antipsychotic activity .

HY-17504B

Rosuvastatin Sodium Maximum Cited Publications 13 Publications Verification ZD 4522 Sodium; X-Plended Sodium; Crestor Sodium	HMG-CoA Reductase (HMGCR) Potassium Channel Autophagy Bacterial	Cardiovascular Disease Metabolic Disease Cancer
Rosuvastatin Sodium is a competitive HMG-CoA reductase (HMGCR) inhibitor, with an IC₅₀ of 11 nM. Rosuvastatin Sodium potently blocks hERG current with an IC₅₀ of 195 nM . Rosuvastatin Sodium reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin Sodium effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .

HY-17504BS2

Rosuvastatin-13C,d3 sodium ZD 4522-₁₃C,d₃ sodium; X-Plended-₁₃C,d₃ sodium; Crestor-₁₃C,d₃ sodium	Autophagy Bacterial HMG-CoA Reductase (HMGCR) Potassium Channel Isotope-Labeled Compounds	Cardiovascular Disease Metabolic Disease
Rosuvastatin- ¹³C,d₃ sodium is ¹³C and deuterated labeled Rosuvastatin sodium (HY-17504B). Rosuvastatin Sodium is a competitive HMG-CoA reductase (HMGCR) inhibitor, with an IC₅₀ of 11 nM. Rosuvastatin Sodium potently blocks hERG current with an IC₅₀ of 195 nM . Rosuvastatin Sodium reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin Sodium effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .

HY-17504

Rosuvastatin Calcium Maximum Cited Publications 13 Publications Verification Rosuvastatin hemicalcium; ZD 4522 Calcium	HMG-CoA Reductase (HMGCR) Autophagy Potassium Channel Bacterial	Cardiovascular Disease Metabolic Disease Cancer
Rosuvastatin Calcium is a competitive HMG-CoA reductase (HMGCR) inhibitor, with an IC₅₀ of 11 nM. Rosuvastatin Calcium potently blocks hERG current with an IC₅₀ of 195 nM . Rosuvastatin Calcium reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin Calcium effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0747

Oxypeucedanin	Cardiovascular Disease Structural Classification Chrysanthemum × morifolium (Ramat.) Hemsl. Classification of Application Fields Source classification Coumarins Phenylpropanoids Umbelliferae Plants Disease Research Fields	Potassium Channel Apoptosis
Oxypeucedanin is a furocoumarin derivative isolated from Angelica dahurica. Oxypeucedanin is a selective open-channel blocker, inhibits the hKv1.5 current with an IC₅₀ value of 76 nM. Oxypeucedanin prolongs cardiac action potential duration (APD), is a potential antiarrhythmic agent for atrial fibrillation . Oxypeucedanin induces cell apoptosis through inhibition of cancer cell migration .

HY-N0747R

Oxypeucedanin (Standard)	Structural Classification Chrysanthemum × morifolium (Ramat.) Hemsl. Source classification Coumarins Phenylpropanoids Umbelliferae Plants	Potassium Channel Apoptosis
Oxypeucedanin (Standard) is the analytical standard of Oxypeucedanin. This product is intended for research and analytical applications. Oxypeucedanin is a furocoumarin derivative isolated from Angelica dahurica. Oxypeucedanin is a selective open-channel blocker, inhibits the hKv1.5 current with an IC₅₀ value of 76 nM.?Oxypeucedanin prolongs cardiac action potential duration (APD), is a potential antiarrhythmic agent for atrial fibrillation . Oxypeucedanin induces cell?apoptosis through inhibition of cancer cell migration .

Cat. No.	Product Name	Chemical Structure

HY-17504AS

Rosuvastatin-d3
Rosuvastatin-d₃ is a deuterium labeled Rosuvastatin. Rosuvastatin (ZD 4522) is a competitive HMG-CoA reductase inhibitor with an IC50 of 11 nM[1]. Rosuvastatin potently blocks human ether-a-go-go related gene (hERG) current with an IC50 of 195 nM, delayed cardiac repolarization, and thereby prolonged action potential durations (APDs) and corrected QT interval (QTc) intervals[2].

HY-W008628S

Bisphenol AP-d5
Bisphenol AP-d₅ is the deuterium labeled Bisphenol AP[1].

HY-17504BS2

Rosuvastatin-13C,d3 sodium
Rosuvastatin- ¹³C,d₃ sodium is ¹³C and deuterated labeled Rosuvastatin sodium (HY-17504B). Rosuvastatin Sodium is a competitive HMG-CoA reductase (HMGCR) inhibitor, with an IC₅₀ of 11 nM. Rosuvastatin Sodium potently blocks hERG current with an IC₅₀ of 195 nM . Rosuvastatin Sodium reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin Sodium effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .

Rosuvastatin-13C,d3 sodium

Rosuvastatin- ¹³C,d₃ sodium is ¹³C and deuterated labeled Rosuvastatin sodium (HY-17504B). Rosuvastatin Sodium is a competitive HMG-CoA reductase (HMGCR) inhibitor, with an IC₅₀ of 11 nM. Rosuvastatin Sodium potently blocks hERG current with an IC₅₀ of 195 nM . Rosuvastatin Sodium reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin Sodium effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

APD

Inhibitors & Agonists

NaturalProducts

Isotope-Labeled Compounds

Natural
Products